Inovio Pharmaceuticals is trading 7.23% higher at $1.78; available coverage has no verified company-specific announcement explaining the November 4 move. - The FDA approval of VOCERYQ and ensuing sharp rally were reported earlier, so they do not explain today’s move. - Major U.S. indexes and the biotech sector are higher, a supportive backdrop that does not establish the cause. - Quarterly results are scheduled for November 10.